Resolutions at the Extraordinary General Meeting in Medivir on 26 January 2018
HUDDINGE, Sweden, Jan. 26, 2018 /PRNewswire/ -- The Extraordinary General Meeting in Medivir Aktiebolag (publ) ("Medivir") on 26 January 2018 resolved, among other things, on the following;
The meeting resolved to authorize the board, for the period up to the annual general meeting 2018, to resolve to issue new shares of series B with deviation from the shareholders' pre-emptive rights. The total number of shares that may be issued under the authorization shall total not more than 20 percent of the number of shares of series B issued as per the date of the meeting.
The meeting further resolved on an additional issue authorization whereby the board is authorized, for the period up to the annual general meeting 2018, to resolve to issue new shares of series B with pre-emptive rights for the company's shareholders. The total number of shares that may be issued under the authorization shall be within the limits of the articles of association, as applicable from time to time.
Issuances of new shares under the authorizations shall be made on market terms and conditions. For further details, refer to Medivir's press release on 2 January 2018.
For further information, please contact:
Erik Björk, CFO
Medivir AB
mobile: +46 (0)72 228 2831.
About Medivir
Medivir is a research-based pharmaceutical company with a focus on oncology. We have a leading competence within protease inhibitor design and nucleotide/nucleoside science and we are dedicated to develop innovative pharmaceuticals that meet great unmet medical need. Medivir is listed on the Nasdaq Stockholm Mid Cap List.
Schools and colleges across the country rely on Immediate Post-Concussion Assessment and Cognitive Testing (ImPACT) evaluations to assess and manage student-athlete concussions on the sidelines. However, this FDA-cleared tool is not recommended for...
MAIA Biotechnology, Inc., ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that independent directors Cristian Luput and Ramiro Guerrero, J.D, LL.M. made individual...
University of Maryland School of Medicine (UMSOM) Dean Mark T. Gladwin, MD, announced today that Martine Rothblatt PhD, JD, MBA, Chairperson and CEO of United Therapeutics, and inventor of SiriusXM Satellite Radio, will deliver the keynote address...
Beghou Consulting announced Thursday several additions to its executive team to support the company's technology innovation, product development and growth initiatives. Dan Cardinal, a Partner at Beghou, will become Chief Technology Officer. The...
Urban Wellness Group, a pioneering wellness provider, is proud to announce its official launch of new anti-aging and sleep enhancement treatments to southeast Portland.
Dr. Jason Zabell and Dr. Andy Swanson set themselves apart by pairing over 30...
Peninsula Canada, a global leading HR and health & safety firm, committed to making a positive impact in the community, is proud to announce a partnership with SickKids Foundation, a leading charity dedicated to supporting The Hospital for Sick...